Delivering a payload across a plasma membrane of a cell includes providing a population of cells and contacting the population of cells with a volume of an aqueous solution. The aqueous solution includes the payload and alcohol content greater than 5 percent concentration. The volume of the aqueous solution may be a function of exposed surface area of the population of cells, or may be a function of a number of cells in the population of cells. Related compositions, apparatus, systems, techniques, and articles are also described.

Provided herein are compositions comprising populations of cells obtained from a pregnant subject comprising at least one of a Hofbauer cell, a cytotrophoblast, a syncytiotrophoblast, an extravillous trophoblast, a villous core stroma, or a fetal vascular cell; a stabilization buffer, wherein the stabilization buffer comprises a preservative; and a cellulosic collection device, wherein at least a subset of the population of cells are intact and inviable and methods of making and using such compositions.

Extracellular vesicles, their manufacture, and methods of treatment are described. Generally, extracellular vesicles can be generated by applying sulfhydryl blocking reagents on animal cells. Extracellular vesicles can be loaded with compounds for an intended use, such as, for example, loading an extracellular vesicle with a medicament to treat an animal. As described here, extracellular vesicles can be generated in a large scale and used for personalized treatments.

Methods of protein production in continuous perfusion mammalian cell culture bioreactors are provided. Methods for continuous perfusion culture by allowing cells to self-regulate the rate of addition of perfusion medium to the bioreactor via a pH change are presented. Compositions comprising the perfusion medium as well as the process advantages of using hi-end pH control of perfusion or HIPCOP are also presented.

Methods and systems for enhancing cell populations such as chondrocytes for tissue engineering applications, e.g., for production of neocartilage. The methods and systems of the present invention feature the introduction of a hypotonic buffer to the cells during the cell isolation process, which results in neotissue (e.g., neocartilage) constructs that are significantly more mechanically robust as compared to those not treated with hypotonic buffer. The methods and systems may further comprise introducing cytochalasin D to cells purified with a hypotonic buffer, which can further bolster the mechanical properties and matrix deposition of the cells. The methods and systems result in neocartilage engineered from chondrocytes, for example, from fetal aged tissue, having compressive properties on par with native adult articular cartilage.

The present invention concerns a process for producing enzymes by a strain belonging to a filamentous fungus, said process comprising two steps: (a) a first step of growing the fungi, in the presence of at least one carbon-based growth substrate, in a stirred and aerated bioreactor in batch phase, at a pH of not more than 4.6; (b) a second step of producing enzymes, starting from the culture medium obtained in the first step (a), in the presence of at least one inductive carbon-based substrate, at a pH of not more than 4.6.

Provided herein are compositions and formulations that are useful for stabilizing one or more bacteria (e.g., through drying). Methods of stabilizing the one or more bacteria are also disclosed.

This disclosure relates to methods of preserving cells for space exploration, methods of culturing cells, and cell growth media. In certain embodiments, methods comprise contacting cells, such as stem cells, induced pluripotent cells, progenitor cells, and cardiac associated cells, with a cell growth medium disclosed herein providing replicated cells. In certain embodiments, methods comprise preserving and culturing cells in outer space comprising; a) freezing cells providing frozen cells; b) transporting the frozen cells to outer space; c) thawing the cells providing thawed cells; and d) culturing the thawed cells with a growth medium disclosed herein.

A glycosylation-modified erythropoietin, containing a glycan structure incorporated into an N-glycosylation site, wherein the glycan structure contains FA4G4L2S4.

The present invention pertains to methods for manufacturing high titer antibody products. In particular, the invention pertains, in part, to improved serum-free animal cell culture medium, which can used for the production of a protein of interest. Additionally, the present invention further pertains to chromatographic procedures employed to successfully isolate the antibody product subject of the present disclosure.